We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). We are focused on developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Treg dysfunction underlies numerous diseases states is driven by the chronic inflammatory environment and high levels of oxidative stress commonly observed in certain diseases. The degree of Treg dysfunction is correlated with the severity and progression of certain serious and life-threatening conditions, making Tregs an important therapeutic target.
We have built a diversified pipeline that includes both ex vivo and in vivo approaches intended to restore the suppressive and immunomodulatory functions of Tregs. Our product candidate pipeline is based on our three distinct therapeutic modalities:
|Treg-Enhancing Biologics||Allogeneic Treg-Derived Exosomes||Auto Treg Cell Therapy|